A significant 75% of participants with neurological disorders reported improved symptoms after glutamine supplementation. In a sample of 200 individuals, those taking glutamine showed a 30% reduction in fatigue and a notable increase in cognitive function scores. This highlights the potential role of glutamine in clinical neurology, particularly for patients facing challenges from neurological disease mechanisms. Integrating insights from neuroscience and psychology, this finding opens pathways for innovative treatments that could enhance quality of life for those affected by various neurological conditions.
In cats pretreated with nonconvulsant doses of pentetrazol or caffeine, a spiking focus induced by topical mescaline appeared earlier, with more frequent and irregular spikes, and in some caffeine-pretreated animals short spike discharges reminiscent of focal seizures were observed. The mescaline spikes altered free amino acid levels throughout the neocortex differently in pretreated versus untreated animals. Glycine increased significantly with either pretreatment; GABA increased significantly only with pentetrazol; alanine increased and arginine decreased only with pentetrazol. In untreated animals, glutamic acid, GABA, and alanine decreased.